SECAUCUS, N.J., Dec. 19, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading national provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a presentation and Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, ...

Core Viewpoint - Quest Diagnostics has shown a positive performance in its stock price, outperforming the S&P 500, but there are questions about whether this trend will continue leading up to the next earnings release [1] Financial Performance - Quest Diagnostics reported Q3 2025 adjusted earnings per share (EPS) of $2.60, exceeding the Zacks Consensus Estimate by 3.59% and up 13% from the previous year [2] - The company's GAAP earnings were $2.16 per share, reflecting an 8.5% increase year-over-year [3] - Revenues for Q3 rose 15.2% year-over-year to $2.82 billion, surpassing the Zacks Consensus Estimate by 3.45% [4] - Diagnostic Information Services revenues increased by 13.5% year-over-year to $2.76 billion, exceeding projections [4] - Volumes measured by requisitions were up 12.5% year-over-year, with revenue per requisition increasing by 0.8% [5] Margin Analysis - The cost of services in Q3 was $1.87 billion, up 11.3% year-over-year, while gross profit rose 17% to $949 million [6] - The gross margin improved to 33.7%, an increase of 110 basis points [6] - SG&A expenses totaled $501 million, up 11.8% from the previous year, with an adjusted operating margin of 15.9%, representing a 132-basis point expansion [6] Financial Position - At the end of Q3 2025, Quest Diagnostics had cash and cash equivalents of $432 million, up from $319 million at the end of Q2 [7] - The cumulative net cash provided by operating activities was $1.42 billion, compared to $858 million a year ago [7] - The company has a five-year annualized dividend growth rate of 7.21% [7] Guidance - Quest Diagnostics updated its full-year 2025 revenue outlook to a range of $10.96-$11.00 billion, indicating a year-over-year increase of 11-11.4% [8] - Adjusted EPS is expected to be in the range of $9.76-$9.84, up from previous estimates [8] Market Sentiment - There has been a downward trend in estimates revision for the stock over the past month [10] - Quest Diagnostics holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [12] - The company has a Growth Score of B, a Momentum Score of F, and a Value Score of B, placing it in the top 40% for value investors [11]

Core Points - Quest Diagnostics will report its third quarter 2025 financial results on October 21, 2025, before market opens [1] - A conference call to discuss the results will take place at 8:30 a.m. Eastern Time on the same day [1] - The call can be accessed via specific phone numbers for domestic and international participants [2] Financial Reporting Details - The earnings release and live webcast will be available on the company's investor website [2] - A replay of the call will be accessible online and via phone from October 21, 2025, until November 5, 2025 [3] Company Overview - Quest Diagnostics provides diagnostic insights to improve health outcomes and serves a significant portion of the U.S. population [5] - The company collaborates with healthcare providers to enhance laboratory testing experiences and health management [6][7]

Core Insights - Quest Diagnostics reported a strong second quarter for 2025, with revenues increasing by 15.2% year-over-year, driven by both organic growth and acquisitions [2][6] - The company raised its full-year guidance for 2025 based on positive performance trends and increased demand for its clinical solutions [2][3] Financial Performance - Net revenues for the second quarter reached $2.76 billion, up from $2.40 billion in 2024, marking a 15.2% increase [2][6] - Diagnostic Information Services revenues also grew by 15.7% to $2.70 billion compared to $2.33 billion in the previous year [2][6] - Adjusted diluted EPS for the quarter was $2.62, reflecting an 11.5% increase from $2.35 in 2024 [2][6] - Operating income rose to $438 million, a 23.3% increase from $355 million in the same quarter last year [2][6] Operational Metrics - Requisition volume increased by 16.3%, while organic requisition volume grew by 2.1% [2][6] - Cash provided by operations for the first half of 2025 was $858 million, up 67.1% from $514 million in 2024 [2][6] Updated Guidance - The updated guidance for full-year 2025 includes net revenues projected between $10.80 billion and $10.92 billion, an increase of 9.4% to 10.6% [3] - Reported diluted EPS is now expected to be between $8.60 and $8.80, while adjusted diluted EPS is forecasted to be between $9.63 and $9.83 [3][6]

Core Viewpoint - Quest Diagnostics Inc. reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of $2.21, exceeding estimates and showing year-over-year growth [1][2][8] Financial Performance - Adjusted EPS of $2.21 beat the Zacks Consensus Estimate by 2.8% and increased by 8.3% compared to the previous year [1] - GAAP EPS was $1.94, reflecting a 12.8% increase from the same quarter last year [2] - Revenues rose 12.1% year over year to $2.65 billion, surpassing the Zacks Consensus Estimate by 1.5% [3] - Diagnostic Information Services revenues increased by 12.7% year over year to $2.59 billion, exceeding projections [3] - Volumes measured by requisitions were up 12.5% year over year, with revenue per requisition increasing by 0.3% [4] Margin and Cost Analysis - Cost of services was $1.79 billion, up 12.2% year over year, while gross profit reached $863 million, an 11.9% increase [5] - Gross margin stood at 32.5%, nearly unchanged from the previous year [5] - SG&A expenses were $476 million, an 8.1% increase from the first quarter of 2024 [5] - Adjusted operating margin improved by 60 basis points year over year to 14.6% [5] Liquidity and Financial Health - Cash and cash equivalents at the end of Q1 2025 were $188 million, down from $549 million at the end of Q4 2024 [6] - Cumulative net cash from operating activities was $314 million, compared to $154 million at the same time last year [6] - The company has a five-year annualized dividend growth rate of 7.17% [6] 2025 Guidance - Full-year 2025 revenue outlook is reaffirmed at $10.70 billion to $10.85 billion, indicating a year-over-year increase of 8.4% to 9.9% [7] - Adjusted EPS guidance remains unchanged at $9.55 to $9.80, with the Zacks Consensus Estimate at $9.68 [7] Market Reaction and Outlook - Following the earnings report, DGX shares gained nearly 6.7% in pre-market trading [2] - The growth in revenue was attributed to a rebound in demand, contributions from acquisitions, and expanded health plan access [8][9]

Core Insights - Quest Diagnostics reported strong revenue growth of approximately 12% in Q1 2025, driven by demand recovery and contributions from acquisitions [2][7] - The company reaffirmed its revenue and adjusted EPS guidance for the full year 2025 [2] Financial Performance - Net revenues for Q1 2025 were $2.652 billion, up from $2.366 billion in Q1 2024, representing a 12.1% increase [2][12] - Diagnostic Information Services revenues increased by 12.7% to $2.589 billion [2][12] - Operating income rose to $346 million, a 15.4% increase from $300 million in the previous year [2][12] - Net income attributable to Quest Diagnostics was $220 million, up 13.2% from $194 million [2][12] - Diluted EPS for Q1 2025 was $1.94, reflecting a 12.8% increase from $1.72 in Q1 2024 [2][12] Operational Metrics - Requisition volume increased by 12.4%, while organic requisition volume decreased by 0.9% [2] - Revenue per requisition saw a slight increase of 0.3% [2] Updated Guidance for 2025 - The updated guidance for net revenues is projected between $10.70 billion and $10.85 billion, indicating an increase of 8.4% to 9.9% [3] - Reported diluted EPS is expected to range from $8.62 to $8.87, while adjusted diluted EPS remains between $9.55 and $9.80 [3][7] - Cash provided by operations is anticipated to be approximately $1.5 billion, with capital expenditures around $500 million [3] Cash Flow and Capital Expenditures - Cash provided by operations in Q1 2025 was $314 million, a significant increase of 103.4% from $154 million in Q1 2024 [2][16] - Capital expenditures for the quarter were $117 million, up 11.9% from $104 million [2][16] Balance Sheet Highlights - As of March 31, 2025, total assets were $15.797 billion, down from $16.153 billion at the end of 2024 [14] - Current liabilities decreased to $1.441 billion from $2.169 billion [14] - Total stockholders' equity increased to $6.962 billion from $6.813 billion [14]